The use of prostate-specific membrane antigen (PSMA)-directed applications in modern
prostate cancer management has evolved rapidly over the past few years, helping to …

Simple Summary Radiolabeled choline and PSMA PET have been largely tested in the
initial staging of prostate cancer and for biochemical recurrence. Moreover, diverse data are …

Here we aim to provide updated guidance and standards for the indication, acquisition, and
interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics …

We aimed to evaluate the role of PET targeting the prostate-specific membrane antigen
(PSMA) for response assessment in metastatic prostate cancer (PCa) patients treated with …

PET with small molecules targeting prostate-specific membrane antigen (PSMA) is being
adopted as a clinical standard for prostate cancer imaging. In this study, we evaluated …

Radiolabelled prostate-specific membrane antigen (PSMA)-based PET–CT has been shown
in numerous studies to be superior to conventional imaging in the detection of nodal or …

Prostate specific membrane antigen (PSMA) represents a validated target for prostate
cancer therapeutics. The phase III VISION study with 177lutetium (177Lu)-PSMA-617 …

Over the years, an increasing proportion of metastatic prostate cancer patients has been
found to experience an initial bone flare phenomenon under both standard therapies …

Our previous study found that the prostate-specific membrane antigen (PSMA) PET/CT
response of primary prostate cancer (PCa) to neoadjuvant therapy can predict the …

Imaging of advanced prostate cancer is a challenging task, as it requires longitudinal
characterization of disease extent in a standardized way to enable appropriate treatment …